This post was originally published on this site To raise funds and disease awareness, as well as to encourage patients, the Lymphoma Research Foundation (LRF) is presenting its annual Light it Red (LIR) for Lymphoma effort. The September-long initiative is aimed at getting buildings and landmarks bathed in red, and getting supporters to wear the color. The…
Conditions
Conditions
FDA Approves Erleada to Treat Metastatic Castration-sensitive Prostate Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation therapy (ADT). The decision is based on the double-blind TITAN Phase 3 trial (NCT02489318), as it showed…
Alzheimer’s Vaccine Found Safe, Effective in Patients with Mild Forms of the Disease, Phase 2 Study Finds
This post was originally published on this site AXON Neuroscience’s investigational AADvac1 vaccine against tau protein, a hallmark of Alzheimer’s disease, was found safe and effective at lessening signs of neurodegeneration in patients with mild Alzheimer’s, according to the results of a Phase 2 trial. Among younger study participants, the vaccine also seemed to improve…
FDA OKs Use of Tool to Predict Patient Response to New Form of Cisplatin in Planned Phase 3 Study
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 clinical trial in people with metastatic breast cancer, Oncology Venture, the company developing both, reports. The FDA is…
FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia
This post was originally published on this site Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and…
‘Be Bold, Be Bald!’ Day for Cancer Organizations Set for Oct. 18
This post was originally published on this site In solidarity with cancer patients, including those with lymphoma, thousands of people throughout the U.S. are expected to sport bald caps Oct. 18 as part of an annual effort called “Be Bold, Be Bald!” to raise funds and awareness. The event — held every year on the…
Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
This post was originally published on this site GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel…
Pain Takes Significant Toll on Ovarian Cancer Survival, Study Shows
This post was originally published on this site For the first time, scientists have found evidence that pain is an independent marker for overall survival in recurrent ovarian cancer, with women with pain living for significantly less time after their diagnosis than those without pain. The survival toll is particularly high for patients with pain…
Effective Responses to the Problem of Elder Abuse
This post was originally published on this site For millions of Americans, elder abuse is an unfortunate consequence of aging. The National Council on Aging (NCOA) estimates that one in 10 seniors ages 60 and older have been abused in the U.S. Physical abuse is just one form of mistreatment that some elderly people endure…
Phase 3 Trials of Elenbecestat in Early Alzheimer’s Stopped for Lack of Benefit, Eisai and Biogen Say
This post was originally published on this site Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This decision was based on a safety review conducted by an independent data monitoring committee that found an unfavorable…
New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows
This post was originally published on this site When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is similar to those seen when the medication is administered intravenously, data from a Phase 3 trial shows.…
Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows
This post was originally published on this site Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases the proportion of people with multiple myeloma who experience a decrease in tumor burden, a Phase 2 trial shows. The results occurred among newly diagnosed patients eligible…